STOCK TITAN

QuidelOrtho Corporation - QDEL STOCK NEWS

Welcome to our dedicated news page for QuidelOrtho Corporation (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on QuidelOrtho Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QuidelOrtho Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QuidelOrtho Corporation's position in the market.

Rhea-AI Summary
QuidelOrtho Corporation (QDEL) receives Health Canada approval for Triage PLGF test, aiding in preterm pre-eclampsia diagnosis and delivery prognosis. The test detects angiogenic imbalance, crucial for maternal and fetal health, with fast results and reduced maternal adverse outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
-
Rhea-AI Summary
QuidelOrtho Corporation (QDEL) announced its participation in the 45th Annual Raymond James Institutional Investor Conference with its management team including the Interim CEO and President. The event will feature a presentation and fireside chat accessible through a live webcast on the company's Investor Relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
conferences
-
Rhea-AI Summary
QuidelOrtho Corporation (QDEL) terminates President and CEO, appoints interim leadership to drive operational efficiency and revenue growth. Board forms Office of the CEO to ensure business continuity. No change in financial guidance. Investor Day postponed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
none
Rhea-AI Summary
QuidelOrtho Corporation (QDEL) reports strong momentum in Labs business with revenue of $743 million in Q4 2023. Non-respiratory revenue increased by 9%, while respiratory revenue decreased by 49%. Full-year 2023 revenue was $3.0 billion, with non-respiratory revenue up 61% and respiratory revenue down 61%. The company received regulatory clearances for new products and made significant debt repayments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.2%
Tags
earnings
-
Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) announced it will report its financial results for Q4 and full year 2023 on February 13, 2024. The company will hold a conference call to discuss the results, with access to the call provided on its website. Presentation materials will also be available on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences earnings
-
Rhea-AI Summary
QuidelOrtho Corporation (NASDAQ:QDEL) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences
Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) has received 510(K) clearance from the U.S. Food and Drug Administration for its Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test, allowing them to market and sell the innovative platform to laboratories performing moderate or high complexity diagnostic testing in the United States. The platform delivers results in 25 minutes or less, improves clinical care, provides cost savings, and delivers sample-to-result molecular testing across all laboratory settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) to Participate in Evercore ISI Conference on November 30, 2023. The company's President and CEO, Douglas Bryant, will join a fireside chat at 9:10 a.m. ET. The live webcast and replay will be accessible on the 'Events & Presentations' section of QuidelOrtho’s Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
-
Rhea-AI Summary
QuidelOrtho Corporation reported third-quarter revenue of $744 million, with strong respiratory demand and growth in non-respiratory businesses. Adjusted diluted earnings per share were $0.90, and adjusted EBITDA was $169 million with a margin of 23%. The company paid down $52 million of debt during the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
earnings
Rhea-AI Summary
Global Lyme Alliance produces chronic Lyme PSA with generous sponsorship from QuidelOrtho
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
QuidelOrtho Corporation

Nasdaq:QDEL

QDEL Rankings

QDEL Stock Data

3.20B
50.59M
7.15%
100.63%
3.65%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
San Diego

About QDEL

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.